Stay updated on Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial page.

Latest updates to the Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial page
- Check4 days agoChange DetectedRevision: v3.6.5 was added. A large block of non-core footer and indexing terms was removed from the page, simplifying the display without changing the core study details.SummaryDifference18%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedRevision: v3.6.4 was applied to the page. This is a back-end update and does not modify the study information, eligibility criteria, or how users interact with the page.SummaryDifference0.1%

- Check25 days agoNo Change Detected
- Check39 days agoChange DetectedThe page's revision tag was updated from v3.6.2 to v3.6.3. This indicates a maintenance update to the page's underlying software rather than changes to study details.SummaryDifference0.1%

- Check46 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.2, signaling a routine maintenance update to the study page. No content changes to the study details or eligibility criteria are indicated by this revision.SummaryDifference0.1%

- Check61 days agoChange DetectedThe study's recruitment status now indicates it is no longer looking for participants, signaling halted enrollment. New help/navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study), and a revision note (v3.6.0) with a formatting change to the Intervention/Treatment header was introduced.SummaryDifference0.6%

- Check68 days agoChange DetectedThe revision tag on the page updated from v3.5.4 to v3.5.5. This indicates a minor page update rather than changes to the study data.SummaryDifference0.1%

Stay in the know with updates to Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial page.